Dipeptidyl peptidase‐4 inhibitors and the risk of community‐acquired pneumonia in patients with type 2 diabetes

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|4|379-385

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.4, 2015-04, pp. : 379-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes

By  

Current Drug Safety, Vol. 6, Iss. 5, 2011-11 ,pp. : 304-309

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Validation and incidence of community-acquired pneumonia in patients with type 2 diabetes in the BIFAP database

By  

Epidemiology and Infection, Vol. 145, Iss. 14, 2017-10 ,pp. : 3056-3064

Cambridge University Press

Access to resources Recommend Favorite

Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 616-621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

By  

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 10, 2015-10 ,pp. : 999-1024

John Wiley & Sons Inc

Access to resources Recommend Favorite